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Summary 
We have developed a functional assay to study the inflammatory capacity of plasma collected 
from patients with severe gram-negative septic shock. In this assay, elutriation-purified, cryo- 
preserved human monocytes from one healthy donor are combined with plasma from patients 
with  severe persistent septic  shock for 5  h.  Subsequently, the  plasma  is  removed, medium 
added, and procoagulant activity (PCA) and secretion of tumor necrosis factor ct (TNF-ot) and 
interleukin 6 (IL-6) measured after 18-h incubation. Plasma from 10 patients (6 died) infected 
with Neisseria meningitidis previously shown to contain high levels of native lipopolysaccharide 
(LPS)  (median 2,700 pg/ml), TNF-o~, IL-6, IL-8, and complement activation products, had a 
low net spontaneous  inflammatory capacity on the monocytes. The median levels of PCA, 
TNF-ot, and IL-6 were 5, 0, and 4%, respectively, of the monocyte activities induced by nor- 
real plasma boosted with purified N.  meningitidis (Nm)-LPS (2,500 pg/ml; net LPS-boosted ca- 
pacity, 100%). The levels ofPCA, TNF-a, and IL-6 obtained with plasma from shock patients 
were  not  different from those  induced by plasma  from  10  meningococcal patients  without 
shock or with plasma from healthy persons. Boosting shock plasma with 2,500 pg/ml Nm-LPS 
had little effect on the monocyte activities since the median values of PCA, TNF-ot, and IL-6 
revealed a minimal increase from 5, 0, and 4% to 9, 2, and 6%, respectively. The shock plasmas 
revealed a strong LPS-inhibitory capacity that was largely absent in plasmas from 10 meningo- 
coccal patients  without shock since the median levels of PCA,  TNF--ot,  and IL-6 increased 
from 5, 0,  and 0% to  135,  51,  and 73%, respectively, after boosting with 2,500 pg/ml Nm- 
LPS. The LPS-inhibitory capacity was closely associated with the levels of IL-10. The median 
levels of IL-10 were  19,000 pg/ml in nine shock patients vs. 22 pg/ml in nine nonshock pa- 
tients with systemic meningococcal disease.  Removal of native IL-10 by immunoprecipitation 
restored the  capacity of plasmas  to  induce monocyte activation either by native LPS  or by 
boosting with Nm-LPS. IL-4 and TGF-[3 were not detected in shock plasmas.  In 24 patients 
with detectable meningococcal LPS (>10 pg/ml, 0.1 endotoxin units/m1), the levels of IL-10 
were correlated to the levels ofLPS (r =  0.79, P <0.001). IL-10 declined from initiation of an- 
tibiotic therapy and paralleled the levels of native LPS. Decreasing levels of IL-10 in serially 
collected shock plasmas were directly related to increasing monocyte responsiveness after Nm- 
LPS boosting. These results suggest that IL-10 plays a major role in containing activation of 
monocytes and possibly other LPS-responsive cells during overwhelming meningococcemia. 
1  ~ystemic meningococcal disease (SMD)  has been a model 
~)infection to  elucidate the  biological effects of LPS  in 
humans.  It is the only gram-negative infection so far stud- 
ied that reveals a dose-dependent association between plasma 
levels of LPS and mortality due to circulatory collapse  (1, 2). 
The circulating levels of native Neisseria meningitidis (Nm)- 
1Abbreviations used in this paper: LAL,  limulus amebocyte  lysate; Nm-LPS, 
purified LPS extracted  from Neisseria meningitidis; PCA, procoagulant  ac- 
tivity; SMD, systemic  meningococcal  disease. 
Portions of  this work were presented  at the 15th Congress of  the Interna- 
tional Society  on Thrombosis and Haemostasis in Jerusalem, Israel, on 
ll-16June 1995 and have appeared in abstract form. 117a. Thromb. Hae- 
mostasis. 1995.73:1087. 
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various  inflammatory mediators  that  cooperatively induce 
septic shock and multiple organ failure (2-4). SMD was the 
first human infection in which bioactive TNF-oe was identi- 
fied as  an  important  mediator  of septic  shock  (5).  Shortly 
after this discovery, a network ofproinflammatory cytokines 
comprising IL-1, -6, -8, and leukemia inhibiting factor (LIF; 
6-10) was identified.  The effects  of the proizlflammatory cy- 
tokines are counterbalanced by several cytokine-neutralizing 
principles such as IL-1 receptor antagonist (IL-lra), soluble 
(s)TNFR p55 and sTNFR p75, and IL-10, all secreted in a 
tightly coordinated manner (4,  10,  11). Several other intra- 
vascular  effector  systems,  including  the  complement,  the 
kallikrein-kinin,  and  the  coagulation  and  fibrinolytic  sys- 
tems, are activated concomitantly with the cytokine network 
during  fulminant  meningococcemia,  revealing  the  very 
complex pathogenesis of human septic shock (3,  12-14). 
With our current knowledge, one would assume that the 
combined effects of exceptionally high levels of LPS, bio- 
active proinflammatory cytokines, and complement activa- 
tion products in plasma from patients with fulminant men- 
ingococcemia  would  exert  a  profound  proinflammatory 
effect on human monocytes and other LPS-sensitive target 
cells  (15).  One  study  has  shown  that  monocytes isolated 
from  patients  with  fulminant  meningococcal  septicemia 
displayed increased synthesis of tissue factor (TF)  that cor- 
related  with  disease  severity  (16).  PBMC  collected  from 
SMD  patients  without  shock  and  studied  ex  vivo  sug- 
gested, however, that spontaneous and LPS-stimulated pro- 
inflammatory cytokine production was downregulated and 
differed markedly from the production oflL-lra during the 
first days of the disease  (17).  The latter observations are in 
line with studies of PBMC collected from other categories 
of septic  shock patients,  indicating  a  dissociation between 
the plasma levels of cytokines and the cytokine production 
in  PBMC  (18,  19).  PBMC  isolated  during  experimental 
human endotoxinemia also reveal a reduced responsiveness 
to LPS stimulation (20). 
With the multitude of potential mediators involved in the 
pathogenesis  of septic shock as well  as naturally  occurring 
neutralizing principles of these mediators, it is presently im- 
possible to predict the net inflammatory effect of septic shock 
plasma on various target cells.  Consequently, we have de- 
veloped a functional assay to study the effect of shock plasma 
on  LPS-responsive  human  ceils.  Normal  human  mono- 
cytes, representing key target cells  for LPS-induced activi- 
ties,  were  combined  with  plasma  collected  from patients 
with  fulminant  meningococcal septic  shock.  The  capacity 
to  activate  monocytes was  compared with  the  results  ob- 
tained with normal plasma boosted with purified Nm-LPS 
and with plasmas  collected from patients  with  SMD  who 
did not develop septic shock. The results indicate that shock 
plasmas contain high LPS-inhibitory capacity that effectively 
counteracts the cooperative action of native meningococcal 
LPS and proinflammatory components that are induced by 
LPS. IL-10 appears to account for much of this antiinflam- 
matory activity. 
Materials and Methods 
Clinical Definitions.  SMD was present if N. meningitidis was cul- 
tivated from blood and/or cerebrospinal  fluid (CSF) or confirmed 
by serology (21).  Shock patients  were those with persistent  hy- 
popeffusion  due  to  bacterial  infection,  with  an  initial  systolic 
blood pressure  of <85 mm Hg in adults  (/>12 yr) and <70 mm 
Hg in children (< 12 yr) that required fluid therapy and treatment 
with vasoactive  drugs  for at least 24 h or until  death.  Nonshock 
patients were SMD patients without persistent hypopeffusion.  Chn- 
ically, the nonshock patients  presented with either meningococ- 
ca1 meningitis or mild systemic meningncoccemia. 
Patient.  Heparin plasmas from 10 patients  (6 too-20 yr-old) 
with shock were studied.  Six patients  died owing to the circula- 
tory collapse and one suffered severe sequelae due to disseminated 
thrombosis.  N.  meningitidis was  isolated  from blood cultures  in 
nine patients  and SMD was diagnosed by serological  tests in one 
patient.  Plasmas from 10 less severely affected SMD patients  (15- 
41-yr-old) without septic  shock were  used  as a control group. 
SMD was confirmed by positive  culture(s)  of blood and/or CSF 
in nine patients  and by serology in one patient. 
The levels oflL-10 were determined in heparin plasma from 9 
of the 10 patients  with and without meningococcal septic shock. 
Samples  were  lacking  for  one  patient  in  each  group.  Subse- 
quently, IL-10 levels were measured in samples from 7 additional 
patients  with meningococcal shock and in 16 samples from men- 
ingococcal patients without shock. Quantitative studies of various 
inflammatory mediators  have previously been  published  on the 
same group of patients  (1, 3, 7, 12-14). 
Nm-LPS.  LPS was extracted from IV.  meningitidis prototype 
strain 44/76 (B:15:P1.16: L,3,7,9) belonging to the ET5 complex 
by genotyping (22). 
Patient Plasma.  Blood was collected in LPS-fi'ee (1), heparinized 
(15 U/ml) vacuum tubes and immediately  centrifuged  (1,400 g, 10 
rain,  20~  plasma  was  pipetted  off,  aliquoted,  and  stored  at 
-70~  in  Cryotubes  (Nunc,  Roskilde,  Denmark)  tested  to be 
LPS-free.  The  samples  used  in  this  assay had  previously been 
thawed. 
The initial plasma samples from both shock and nonshock pa- 
tients  were collected within  6 h  of hospital  admission.  Samples 
were collected serially from many patients  with shock in 2-12-h 
intervals. 
Control Plasma.  Heparinized  blood  was  collected  from  one 
healthy  adult  and processed as above.  An  LPS-positive  control 
was prepared by adding 2,500 pg Nm-LPS to 1 ml heparin plasma 
and vigorously mixed at room temperature (20~  Plain heparin 
plasma was used as negative control. 
Plasma Endotoxin Assay.  Native meningococcal LPS  in hep- 
arin plasma was quantified  by the limulus  amebocyte lysate (LAL) 
assay, as previously described in detail  (1,  23).The lower detec- 
tion limit was 4 pg/ml (23). 100 pg of the LPS standard  equalled 
1 endotoxin unit (EU).  The high levels of neisserial lipid A have 
previously been verified  by gas chromatography and mass spec- 
trometry in plasma from several patients  (22). 
Acid-treated FCS.  FCS  (Flow Laboratories,  Irvine,  Scotland) 
tested  to contain <100 pg/ml of LPS was prepared as described 
previously (24), aliquoted,  and stored at -20~ 
Cell Culture Fluid (Acid-treated-FCS-RPMI).  19,300 ~1RPMI 
and  25  mM  Hepes  buffer with  L-glutamine  (GIBCO,  Paisley, 
Scotland,  UK) was supplemented with 500 ~1 acid-treated (AT)- 
FCS and 200 ~L1 penicillin/streptomycin solution (Sigma Chemi- 
cal Co., St. Louis), mixed, and stored at 4~ 
Glucose Phosphate Buffer.  The buffer contained 0.14 M  NaC1, 
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to pH 7.4 with 1 N  HC1. 
Preparation of PBMC.  PBMC were prepared  from one healthy 
donor by density gradient centrifugation and further purification 
of monocytes by  centrifugal  elutriation,  as  described  (24,  25). 
Cryopreservation and thawing of these cells were done according 
to procedures described  in detail elsewhere  (24). 
Assaying the Net Inflammatory Capacity of Plasma.  Monocytes 
(5  ￿  104 suspended in 80 pJ FCS-RPMI/well) were seeded in 
microtiter plates (Dynatech; Ludwigsburg, Germany). 120 p,1 pa- 
tient plasma, positive and negative control plasmas, was added to 
duplicate  wells,  the plate  sealed off and incubated for 5 h  (37~ 
5% CO2). The plate  was then centrifuged (47 g,  5 min,  20~ 
and  the  supernatant  gently removed and  discarded.  The  wells 
were washed once with glucose phosphate buffer (GPB),  centri- 
fuged as above, the supernatant discarded,  and 200 p,1 AT-FCS- 
RPMI added to each well. The plate was sealed off and incubated 
for 18 h  (37~  5% CO2)  before the supematants were pipetted 
off and stored at  -70~  until assayed for TNF-ot and IL-6. The 
cells were  harvested and stored in 75  I~1 barbital  buffer (26) at 
-70~  until assayed for procoagulant activity (PCA)(25). 
PCA Clot Assay.  This assay was performed essentially accord- 
ing to the method of  Jungi (27) as modified by Osnes et al. (25). 
Immunoassay.  Immunoassays of human IL-4, TGF-J], TNF-ot, 
IL-6 (R. & D  Systems,  Abingdon, UK),  and IL-10 (Biosource, 
Camarillo, CA) were performed according to the manufacturers' 
instructions. 
Recombinant Human IL-IO.  (1-2 ￿  106 U/mg rhlL-10, >97% 
pure) was purchased from tk & D Systems. 5 p~g rhlL-10 was dis- 
solved in 2 ml PBS containing 0.2% (wt/vol) BSA (Sigma Chem- 
ical Co.), final concentration 2.5 ng/p,1 or 2.5-5 U/pA. 
Polyclonal Goat Anti-human rlL- 10 Antibodies.  1 mg/ml of  these 
antibodies  was purchased from 1~ & D Systems. 
The Effect of Boosting LPS-positive Control Plasma with rhlL-lO. 
2 U  rhlL-10 was added to each well with the positive control 
plasma  and PCA monitored.  The PCA was 6%  of the positive 
control  and  equal  to  the  negative  control,  indicating  the  pro- 
found inhibitory effect  of IL-10 on monocyte activation in our 
assay. 
Immunoprecipitation of rhlL-lO in Control Plasma.  600  ILl hep- 
arinized  control plasma was boosted with 4 p~l (10-20 U) rhlL-10 
and vortexed. The level ofrhlL-10 was shown to be >500 pg/ml. 
50  pA (50  p,g) of polyclonal goat anti-human  IL-10 was added; 
the sample was first incubated for 1 h at 37~  with gentle agita- 
tion, and again for 18 h at 4~  and then centrifuged (3,000 g, 30 
rain,  4~  (28).  The  supernatant  of the  immunoprecipitated 
plasma was pipetted offand shown to contain <15 pg/ml rhlL-10. 
When the supernatant was boosted with 2,500 pg/ml Nm-LPS, 
the monocyte activities  were restored to close to normal values, 
i.e.,  71% PCA, 99% TNF, and 72% IL-6, respectively.  To con- 
trol for possible unspecific  monocyte activation by remaining im- 
mune  complexes,  the  IL-10-depleted plasma  was  added to the 
target  monocytes and  monitored  for PCA,  TNF-er  and  IL-6. 
The levels of PCA (4%), TNF-ot (3%), and IL-6 (1%) were not 
different  from the negative control, indicating that remaining im- 
mune complexes did not stimulate  the monocytes. 
Immunoprecipitation of Native IL- I O in Patient Plasma.  50  p,1 of 
goat anti-human rlL-10 was added to 600 p,1 patient plasma, the 
samples mixed, incubated, and centrifuged as above. The effect of 
the immunoprecipitation was evaluated in plasma from four pa- 
tients  with  shock  that  had  initially  contained  44,600,  24,400, 
11,100,  and 1,940  pg/ml of IL-10. The levels were reduced by 
/>99.5%. 
Statistics.  The differences between groups were calculated with 
the Mann-Whitney U test. The correlation coefficient was calcu- 
lated with the Spearman rank test.  P values  <0.05 were consid- 
ered statistically significant. 
Results 
Levels  of Native  Nm-LPS  in  Patient  and  Control Plasma. 
The  median  level  of native  Nm-LPS  in plasmas  from  10 
patients with severe persistent septic shock was 2,700 pg/ml 
(range  50,000-1,100  pg/ml)  by  LAL  assay.  One  patient 
sample  with  50,000  pg/ml  was  diluted  1:5  with  normal 
plasma before assaying. When apphed to the target mono- 
cytes, the  median in-well  concentration of native Nm-LPS 
was 320 pg (range 1,260-130 pg). 
Plasma  from 3  of 10  nonshock patients  contained  110, 
20, and 13 pg/ml native LPS, respectively, whereas samples 
from  7  nonshock  patients  were  without  detectable  LPS 
(<4  pg/ml)  by LAL assay.  The  control plasma  contained 
2,500  pg/ml  purified  Nm-LPS,  equivalent  to  an  in-well 
concentration of 300 pg, which was verified by LAL assay. 
Net Spontaneous Inflammatory Capacity (PCA, TNF-c~, IL-6) 
Induced by Plasma  from Shock Patients.  The median level of 
monocyte-generated PCA for the whole group was 9% of 
the  positive  control plasma  (range  0~  Fig.  1 A).  The 
median level of secreted TNF-ot was 0% (range 0-5%) and 
IL-6 was  4%  (range  0-29%),  respectively,  of the  positive 
control  plasma  (Fig.  1  A).  These  levels  were  not  signifi- 
cantly different from those obtained with the negative con- 
trol  plasma  that  averaged  2,  2,  and  0%,  respectively,  for 
PCA, TNF-ot, and IL-6. 
The  results  indicate  that plasmas  from patients  with  se- 
vere,  persistent,  and  often fatal  septic  shock induced little 
or no activation of normal human monocytes as monitored 
by PCA, TNF-et, and IL-6. 
Net  Spontaneous  Inflammatory  Capacity of Plasma from 
Nonshock Patients.  Samples  from  10  SMD  patients  with- 
out septic shock were studied. The median levels ofmono- 
cyte-generated PCA were  5%  (range  0--12%),  1% TNF-ot 
(range  0-2%),  and  0%  IL-6 (range  001%)  of the  activities 
induced  by  the  positive  control  plasma  (Fig.  1  C).  One 
sample was missing in the analysis of TNF-ot and IL-6. The 
levels of PCA and TNF-ot were not significantly different 
from those obtained with shock plasmas or with the nega- 
tive  control  (P  ~0.32),  whereas  the  levels  of IL-6 were 
lower in nonshock than shock plasma (P =  0.03). 
Net  Inflammatory  Capacity of Plasma from  Shock  Patients 
Boosted with Purified Nm-LPS.  Samples  from 7  of the  10 
shock patients previously studied were assayed. Each sam- 
ple  was  boosted  with  2,500  pg/ml  Nm-LPS  giving  the 
same in-well concentration (300 pg/well)  of purified Nm- 
LPS as in the positive control plasma.  The median mono- 
cyte-generated activities were: 9% PCA (range 3--43%), 2% 
TNF-ot (range 0-5%), and 6% IL-6 (range 0011%), respec- 
tively, compared with the positive control (Fig.  1 B).  The 
value for IL-6 was missing for one patient.  Purified  Nm- 
LPS  added  to  shock  plasma  thus  induced  a  minimal  in- 
crease of PCA and no increase in TNF-ot and IL-6 levels. 
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Figure 1.  Net spontaneous (A and C) and LPS-boosted (B and D) in- 
flammatory capacity of plasmas from 20 patients with SMD, 10 patients 
with shock, and 10 patients without shock. The values are given as per- 
cent activity (100%) induced by the positive control, i.e., plasma, from a 
healthy donor boosted with 2,500 pg purified Nm-LPS per ml. 
Net Inflammatory Capacity of Plasma from Nonshock Patients 
Boosted with Purified Nm-LPS.  Plasmas  from  the  10  non- 
shock  patients  were  boosted  with  2,500  pg/ml  Nm-LPS 
(300  pg Nm-LPS/well)  as above.  The median monocyte- 
generated  activities  were:  135%  PCA  (range  57-200%), 
51%  TNF-ot  (range  5-119%),  and  73%  IL-6  (range  12- 
167%)  of the  positive  control  (Fig.  1  D).  The  levels  of 
PCA, TNF-cx, and IL-6 were significantly higher (P ~<0.001) 
than  observed with  shock  plasma boosted with  Nm-LPS. 
PCA was significantly more upregulated than TNF-~x (P = 
0.007)  and IL-6 (P =  0.03),  whereas no  significant differ- 
ence existed between TNF-oL and IL-6 (P =  0.23). The re- 
sults  indicated  that  plasma  from  nonshock  patients  with 
SMD  differed markedly from shock plasmas in the  ability 
to induce monocyte activation after boosting with Nm-LPS. 
Net Spontaneous Inflammatory Capacity in Sequentially Collect- 
ed Samples  fiom Shock Patients.  Previous studies have shown 
that native Nm-LPS declines with q/2 varying from 1 to 3 h 
after initiation of antibiotic and fluid therapy (1). In serially 
collected plasma samples from  three patients with initially 
high levels of native LPS, the spontaneously generated lev- 
els of PCA,  TNF-c~, and IL-6 were  ~<29%  of the positive 
control as long as LPS was detectable by LAL assay (Table 1). 
The LPS-inhibitory  Capacity of Patient Plasma.  The differ- 
ence in levels ofPCA, TNF-ot, and IL-6 between the LPS- 
boosted and native plasma was defined as the LPS-inhibitory 
capacity of a patient plasma. A  small difference indicated a 
large  LPS-inhibitory capacity.  In  patients with  shock,  no 
significant differences existed (P >0.05 for all three param- 
eters) between LPS-boosted and unboosted plasmas. Thus, 
the  LPS-inhibitory  capacity was  high  (Fig.  1,  A  and  C). 
In plasmas from nonshock patients, highly significant differ- 
ences  existed  between  LPS-boosted  and  native  plasmas 
(P ~<0.001),  indicating  that  the  LPS-inhibitory  capacity 
was significantly lower than observed in shock plasmas (Fig. 
1, B and D). 
Changes  in  the  LPS-inhibitory  Capacity  of Shock  Plasma 
Over Time.  Serially collected plasmas  from  four  patients 
that  initially contained  14,000,  10,500,  3,800,  and  2,500 
Table  1.  The Relation between Native Meningococcal LPS, 
IL-10, and Net Spontaneous Inflammatory Capacity 
IL-IO present  IL-IO removed 
Native  Native 
No.  h  LPS  IL-10  PCA  TNF  IL-6  PCA  TNF  IL-6 
*  pg/ml  %  % 
1.1  1  I0,500:~ 40,000~  27  16  8  >254  127  142 
1.2  8  700  7,000  4  1  5  26  9  10 
1.3  11  400  5,000  1  8  3  11  11  3 
1.4  15  200  2,800  3  6  1  10  13  2 
1.5  28  <25  170  2  5  0  4  3  0 
2.1  11  2,700  -  3  1  0  228  186  74 
2.2  15  190  1,800  2  7  0  11  9  3 
2.3  82  <25  66  1  7  0  1  2  0 
3.1  6  2,600  16,500  4  1  29  51  22  33 
3.2  19  380  410  2  4  7  4  2  4 
4.1  6  1,000  1,170  4  2  5  147  50  83 
5.1  8  120  14,000  2  5  1  4  3  l 
The net spontaneous inflammatory capacity (PCA, TNF-ix, IL-6) of se- 
quentially collected plasmas (n =  12) from five patients with meningo- 
coccal shock (1-5) before and after immunoprecipitation  oflL-10. The 
values are given as percent monocyte activity induced by the positive 
control,  i.e., plasma, from a healthy donor boosted 2,500 pg purified 
Nm-LPS per ml. 
*Hours after antibiotic therapy was initiated. 
*Levels of Nm-LPS generated in vivo in patient samples as determined 
by LAL assay. 
~Levels of IL-10 generated in vivo as determined by ELISA. 
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studied.  The  LPS-inhibitory  capacity  was  tested  using 
paired  samples  of native  shock  plasma  and  shock plasma 
boosted with purified Nm-LPS (2,500 pg/ml).  The LPS- 
inhibitory capacity changed markedly during the first 24 h 
as indicated in Fig. 2, A-D. The levels of PCA and IL-6 in 
LPS-boosted plasmas  increased from <10% to  >100%  of 
the  positive control  15-20  h  after initiation  of the  anti- 
shock therapy. In three of  four patients the levels of TNF-ot 
in  LPS-boosted plasmas  were less  upregulated  than  were 
the levels of PCA and IL-6, indicating a complex and fine- 
tuned regulation of different monocyte activities. 
Quantitation  of IL-4,  IL-IO,  and TGF-[3 in Patient  Blood 
Samples.  IL-4 (detection limit, 4 pg/rnl) and TGF-13 (de- 
tection limit,  31  pg/ml)  were not detected in any of the 
plasma  samples  with  high  LPS-inhibitory  capacity.  The 
levels  of IL-10 were  initially determined in  9  of the  10 
samples from patients with and without shock. The median 
level  of IL-10  in  the  shock  plasmas  was  19,000  pg/ml 
(range  1,800--111,000  pg/ml)  vs.  22  pg/ml  (range  <15- 
4,400 pg/ml)  among 9  of 10 plasmas  from nonshock pa- 
tients.  One sample for IL-10 analysis  was lacking in each 
patient group. 
Subsequently, IL-10 was determined in plasma from 23 
additional patients with SMD,  7 with shock and  16 with- 
out shock. Among 16 shock patients, IL-10 was present in 
all and the median level was  13,300 pg/ml  (range  1,800- 
111,000 pg/ml; Fig. 3). Of 25 patients without shock, IL-10 
was present in  17 (68%;  Fig. 3). The median level was 44 
pg/ml (range <15-4,400 pg/ml).  The difference in levels 
of IL-10 was  highly significant between shock and  non- 
shock patients  (P =  0.0001;  Fig.  3).  The levels of IL-10 
were significantly correlated with the levels of native LPS 
(r =  0.79, P =  0.0002, n =  24). 
Disappearance of the LPS-inhibitory  Capacity  Versus Declin- 
ing Levels of lL- l O in Plasma.  An  inverse  relation  existed 
between declining levels of IL-10 and increasing monocyte 
reactivity after stimulation with Nm-LPS (2,500 pg/ml) in 
serially collected shock plasmas  (Fig. 2, A-D). Levels of na- 
tive IL-10 >1,000 pg/ml were associated with significant 
LPS-inhibitory capacity.  Levels  of IL-10  <1,000  pg/ml 
were associated with reduced LPS-inhibitory capacity, i.e., 
increasing monocyte reactivity when stimulated with Nm- 
LPS (Fig.  2, A-D).  The levels of PCA and IL-6 increased 
to  >150%  of the  positive control when monocytes were 
stimulated with shock plasma containing <1,000 pg/ml of 
IL-10 boosted with Nm-LPS (Fig.  2, A-D).  The levels of 
IL-10 declined from the initiation of antibiotic and anti- 
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Figure 2.  The levels of monocyte-generated  PCA (closed  circles) and secreted  TNF-a (closed  squares), and IL-6 (closed  triangles) elicited  by plasma from 
four different  shock patients collected  serially and boosted with 2,500 pg/ml of purified Nm-LPS. The values are given as percent positive control 
(healthy donor plasma boosted  with 2,500 pg/ml Nm-LPS). (Dashed  line) Levels  oflL-10. 
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shock; n =  25). (Dashed line) Detection 
limit (15 pg rhlL-10/ml). (Bars) Median 
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shock therapy and paralleled  the  declining levels  of native 
Nm-LPS (Fig. 4, A-D). 
The Net Inflammatory Capacity of Shock Plasmas Depleted of 
IL-10.  12 plasma samples from 5 shock patients collected 
serially during the acute stage of the disease were inmmno- 
depleted oflL-10 (Table  1).  10 of 12 plasmas contained na- 
tive meningococcal LPS ranging from 10,500 to  120 pg/ml 
by LAL assay.  LPS was <25 pg/ml in two samples. 4 of 12 
samples contained native LPS concentrations of >700 pg/ml. 
Before IL-10 depletion, all plasmas showed low net sponta- 
neous inflammatory capacity (Table  1).  Removal of IL-10 
by immunoprecipitation  increased the spontaneous net in- 
flammatory  capacity  dramatically  in  samples  containing 
>700 pg/ml of native meningococcal LPS (Table 1). IL-10-- 
depleted plasmas with native LPS <700 pg/ml had little or 
no effect on the monocytes (Table 1). After immunodeple- 
tion,  there  was  a  close  correlation  between  the  LAL- 
detected  LPS  activity  in  the  IL-10-depleted  plasmas  and 
their capacity to induce PCA (r =  0.91, P =  0.006), TNF-ot 
(r =  0.81, P  =  0.02), and IL-6 (r =  0.92, P  =  0.006) in the 
target monocytes. 
The Net Inflammatory Capacity of Shock Plasmas Depleted of 
IL-I0 and Boosted with Nm-LPS.  Boosting  IL-10-depleted 
patient  plasmas  with  the  standard  amount  of  Nm-LPS 
(2,500  pg/ml)  restored  the  capacity  to  stimulate  mono- 
cytes. This was particularly evident for plasmas with native 
LPS <700 pg/ml since the median levels ofPCA, TNF-~x, 
and IL-6 increased from 7, 6, and 3%, respectively,  before 
LPS stimulation,  to  118,  91,  and  120% after LPS stimula- 
tion. When Nm-LPS was added to the four IL-10-depleted 
plasmas with native LPS >700 pg/ml, the median levels of 
PCA,  TNF-ot,  and  IL-6 went  from  188,  89,  and  79%  to 
206,  107, and 131%, respectively. 
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The relation between native Nm-LPS (closed  circles)  and IL-10 (dashed  line) in serially collected  plasma samples from the four patients in Fig. 2. 
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We have developed a functional assay to study the im- 
pact of highly pathological plasma,  collected from patients 
with severe gram-negative septic shock on normal human 
monocytes.  A  large  number  of experiments  were  per- 
formed under strictly standardized conditions by combin- 
ing purified, cryopreserved, and functionally active human 
monocytes from a healthy donor with pathological plasmas 
from different patients. The assay system was constructed to 
monitor three different monocyte functions that represent 
activation  of  "immediate  early  genes"  after  stimulation 
with LPS. These functions are mediated by CD14 and are 
closely coordinated in their expression (25).  This approach 
also  gave us the possibility to study the net effect of vari- 
ous pro- and antiinflammatory components generated dur- 
ing overwhelming gram-negative sepsis.  Furthermore, the 
method made it possible to study the effect of native LPS 
generated during severe gram-negative bacteremia vs.  the 
purified LPS usually employed in experiments. 
Surprisingly,  plasma  collected  from  severely  ill  septic 
shock  patients  with  exceptionally  high  levels  of native 
meningococcal LPS and bioactive proinflammatory cyto- 
kines  did not  activate the  monocytes. When the  samples 
were boosted with purified Nm-LPS, they remained partly 
or completely inactive, suggesting that inhibitory compo- 
nents were present in the plasmas  that effectively antago- 
nized the proinflammatory components, in particular LPS. 
This LPS-inhibitory capacity declined gradually after anti- 
biotic  and  antishock  treatment  was  initiated,  but  was 
present during the whole elimination phase of native LPS. 
Thus, minimal or no spontaneous activation of the donor 
monocytes occurred in sequentially collected samples. 
When  purified Nm-LPS  was  added  to  plasma  samples 
collected 12-36 h after hospital admission, increasing mono- 
cyte responsiveness was present, reflecting reduced inhibi- 
tion of the monocytes. The PCA and IL-6 responses grad- 
ually surpassed the response obtained with Nm-LPS added 
to normal donor plasma,  indicating the presence of proin- 
flammatory components that acted synergistically with pu- 
rified LPS.  This  rapid  shift  in  the  inhibitory capacity of 
shock plasma over time suggested that the inhibitory prin- 
ciple(s) disappeared with a kinetics similar to that of various 
cytokines, i.e.,  TNF-o~, IL-6,  IL-8,  and LIF in fulminant 
meningococcal septicemia (7-9, 11). 
The inhibition of Nm-LPS-induced monocyte activity 
was absent or only weakly present in plasma collected upon 
hospital admission from patients with  SMD who did not 
develop severe septic shock. The latter group is character- 
ized by "low" (<700 pg/ml) or undetectable levels of na- 
tive meningococcal LPS and low levels or absence of bio- 
active TNF-ci, IL-6, and complement activation products 
upon  admission  (1-5,  7,  8,  12-14).  The acute phase  re- 
sponse is  massive,  upon  admission,  in  the  latter group  of 
patients  as  reflected by high  levels  of C-reactive  protein 
and fibrinogen. In patients with fulminant meningococcal 
septicemia, the acute phase response is less pronounced be- 
cause of the shorter duration of symptoms before hospital 
entrance. The behavior of the inhibitory principle(s) in se- 
quentially collected shock samples  and among the different 
clinical categories was clearly different from the behavior of 
common acute phase reactants. 
TGF-{3, IL-4,  and  IL-10 are all cytokines with antiin- 
flammatory properties  that  may  downregulate  monocyte 
functions (29-36).  The patient plasmas  were screened for 
the presence of any of the three. High levels of IL-10 were 
present in all shock plasmas.  In plasmas from SMD patients 
without shock, the levels of IL-10 were several magnitudes 
lower or absent, i.e.,  <15  pg/rrd.  IL-4 and TGF-J3 were 
not detected in any plasmas with high graded inhibitory ca- 
pacity. The levels of lL-10 declined, furthermore, in paral- 
lel with the reduction of the inhibitory capacity of serially 
collected shock plasma. 
Removal of IL-10 by immunoprecipitation restored the 
capacity of shock plasma to react with purified Nm-LPS. 
After removal of in vivo-generated IL-10, several plasmas 
with high levels of native meningococcal LPS, i.e.,  >700 
pg/ml,  induced  PCA,  TNF-o~,  and  IL-6  in  the  target 
monocytes without being boosted with purified LPS. We 
assume  that  native  LPS  together  with  proinflammatory 
plasma  components induced this activity. In patients with 
low levels of both native LPS (~<700 pg/ml or 7 EU/ml) 
and proinflammatory cytokines, minimal  or no upregula- 
tion of monocyte activities occurred aiier removal of  in vivo- 
generated IL-10, indicating that the procedure per se, i.e., 
formation of immune complexes, did not activate the cells. 
These results demonstrate that IL-10 is abundantly present 
in plasma from patients with meningococcal septic shock, 
an observation that is in accordance with that of other re- 
search  groups  (10,  37).  The plasma  levels of IL-10 were 
closely associated with the circulating level of native LPS, 
as has previously been documented for several proinflam- 
matory cytokines (3, 4, 7).  IL-10 appears, furthermore, to 
play an  important  functional  role  in  deactivating mono- 
cytes and possibly also tissue macrophages in vivo. Genera- 
tion of IL-10 in animal experiments has been related to the 
development  of endotoxin tolerance  (38).  Our  observa- 
tions suggest that IL-10 might play an important functional 
role in downregulating the  response of human  monocyte 
to LPS in human bacteremia and endotoxinemia, explaining 
the deactivated state of PBMC during septic shock and ex- 
perimental human endotoxinemia (18-20). In our patients, 
it represented an important antiinflammatory cytokine with 
a  strong impact on the  functional state  of the  monocytes. 
The antiinflammatory effect of IL-10 alone was apparently 
stronger than the collective action of bioactive native LPS, 
TNF-oL, IL-6, IL-8, complement activation products, and 
other proinflammatory components in plasma in determin- 
ing the functional state of monocytes. These observations 
suggest that IL-10 plays a key role in modulating the intra- 
vascular  inflammatory  response  in  overwhelming  sepsis 
rendering plasma  antiinflammatory as  concerns monocyte 
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negative feedback loop to contain the effect of excessively 
produced proinflammatory cytokines. 
We  have  previously observed that  isolated  monocytes 
collected from two patients with fulminant meningococce- 
mia with massive  coagnlopathy were in a deactivated state. 
These monocytes, which were collected 12 h after hospital 
admission and purified by elutriation, did not secrete TNF-0e, 
IL-6, or express TF spontaneously as determined by flow 
cytometry and in a microclot assay of lysed cells. The cells 
lacked mRNA for TNF-ci and IL-6, whereas mRNA for 
IL-8 was present. They were unable to respond to purified 
Nm-LPS (Brandtzaeg, P., unpublished results). 
IL-10 was present in all patients with fulminant menin- 
gococcal septicemia and in two thirds of all patients with 
mild systemic meningococcemia. The median level in the 
former group was  300  times higher than was  the median 
level in patients  without persistent septic  shock.  IL-10 is 
elicited  during  experimental  human  endotoxinemia  and 
the levels are attenuated by a fragment of bactericidal per- 
meability increasing protein that blocks the biological effect 
of lipid A  (39).  It is secreted by monocytes, and by tissue 
macrophages including the large population of Kupffer cells 
in the liver. Animal experiments have shown that lethality 
increases if the action of IL- 10 is blocked (40, 41). Increas- 
ing  severity,  as  reflected by increasingly higher levels  of 
native  LPS  upon  admission,  was  associated  with  a  dose- 
dependent increase in IL-10 levels in our patients. This ob- 
servation is in line with previous results linking increasing 
bacterial proliferation, and  consequently, increasing levels 
of native LPS to a dose-dependent increase in various cy- 
tokines in fulminant meningococcal infections (3, 42). The 
levels of IL-10 declined immediately after the bacterial pro- 
liferation and production of  LPS was terminated by penicil- 
lin treatment. The declining levels of IL-10 paralleled the 
levels of native meningococcal LPS closely. The cells that 
produce IL-10 appear to recognize the absolute levels of na- 
tive LPS and produce IL-10 accordingly. In patients devel- 
oping fulminant septicemia,  the production of IL-10 ap- 
pears to increase until antibiotic therapy is initiated. When 
the microbial growth is terminated and circulating LPS de- 
cline due to elimination, the production of IL-10 is gradu- 
ally downregnlated, reducing the circulating plasma levels 
to  a  few picograms  per  milliliter within  10-40  h.  IL-10 
clearly circulates in a biologically active form as was dem- 
onstrated by immunoprecipitation experiments. 
Although  IL-10  appears  to  be  a  key antiinflammatory 
cytokine that accounts for much of the inhibitory activity 
in septic shock plasma,  it is presumably not the only antiin- 
flammatory  cytokine  elicited.  Increased  levels  of IL-lra 
have previously been documented in meningococcal septic 
shock plasma (4). Experience, so far, has shown that a com- 
plex cytokine network exists,  comprising molecules with 
overlapping activities. This is also the case for downregula- 
tion of cytokine action  (43).  Presumably, there are more 
antiinflammatory principles that have yet to be identified. 
Some of our observations indicated that LPS-inhibitory ca- 
pacity cannot completely be explained by IL-10 alone.  In 
certain plasmas  from nonshock patients,  stimulation  with 
Nm-LPS had little impact on TNF-o~ and IL-6 production 
despite undetectable levels of IL-10.  In plasmas  from two 
of four patients examined serially,  LPS-inhibitory capacity 
as concerns PCA, reached its maximum 5-7 h after admis- 
sion when the IL-10 levels had declined to 30-40% of the 
admission levels (Fig.  2,  B and  C).  This may indicate that 
the  complex balance between pro-  and  antiinflammatory 
principles in plasma had changed over time. The changing 
balance may also  have a different impact on the different 
monocyte functions since PCA appeared to be more sensi- 
tive to the changes than secretion of TNF-0e and IL-6. 
In our assay system, samples containing native LPS >700 
rig/liter revealed a  significantly higher monocyte activity 
after removal of IL-10 than did samples  with lower levels 
of LPS. The latter samples  induced virtually no monocyte 
activity despite removal of IL-10. This may primarily relate 
to the sensitivity of the assay system, but could also partly 
be  explained by the  interaction  of native  meningococcal 
LPS with various LPS-neutralizing buffer systems in plasma, 
primarily lipoproteins (44,  45). These systems may prevent 
cell activation by low levels of LPS but not the excessively 
high  levels  observed  in  fulminant  meningococcal  septic 
shock. 
The results of this study suggest that the antiinflammatory 
principles in septic shock plasma have a stonger impact on the 
activation state  of human  monocytes than  do  the  proin- 
flammatory principles. Certain fundamental questions arise 
from these observations. Are LPS-responsive cells other than 
monocytes also deactivated by septic shock plasma?  In par- 
ticular,  are neutrophils impaired in their phagocytic function 
by IL-10  and  possibly  other  antiinflammatory cytokines? 
What  is  the  effect of shock  plasma  on  endothelial  cells, 
smooth muscle cells,  and platelets?  To answer these ques- 
tions, the functional role of IL-10 on other LPS-responsive 
cells  has  to  be  elucidated.  Assays built  according  to  the 
same principles as the one used in this study may help to 
disclose  the net effect of septic shock plasma on important 
target  cells  that  contribute  to  the  development of septic 
shock. We believe that this assay combined with immuno- 
precipitation can also be used to study the functional role of 
other plasma components that are assumed to play an im- 
portant role in regulating cell activation during intravascu- 
lar inflammation. 
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